aspirin / Generic mfg. - LARVOL DELTA

Cutaneous Adverse Drug Reactions and Drug Hypersensitivity in Pediatric Emergency Visits: A National Electronic Injury Surveillance System Analysis in the United States, 2022–2024 (AAD 2026) - "Non-aspirin oral tablets and capsules were the most commonly implicated drug category, accounting for 53% of all cases...By delineating frequent ADR profiles by demographic and clinical characteristics, we highlight key risk factors and propose opportunities for improved recognition, diagnosis, and prevention—particularly for DH and anaphylaxis among young children. Enhanced awareness and safety measures can reduce the impact of ADRs in this vulnerable population."

Adverse drug reaction • Clinical • Immunology • Pediatrics

Evaluation of a Novel Over-the-Counter Shaving Kit in the Management of Pseudofolliculitis Barbae: A Pilot Study (AAD 2026) - "Patients with an aspirin allergy were excluded... This new over-the-counter shaving kit demonstrated promising short-term efficacy in reducing symptoms in patients with PFB who require regular shaving. Although limited by small sample size and short follow-up, these findings suggest potential utility for active-duty and other populations where shaving cannot be avoided. Larger controlled studies are warranted to validate these results."

Clinical • Immunology

Evaluation of Venous Thromboembolism (VTE) Prophylaxis in Multiple Myeloma Patients on Immunomodulatory Drugs (IMiDs) at VA Puget Sound (HOPA 2026) - "New starts are defined as patients who had not received pomalidomide or lenalidomide in the past and those who had restarted IMiDs but not on any IMiDs for at least 4 months...Bleeding episode occurred in four patients, in which two of them were on apixaban 5mg BID for atrial fibrillation had developed GI bleed. Of the two on aspirin, one developed VTE and had GI bleed from the VTE treatment, and the other had GI bleed who was deconditioned and had a history of GI bleed... Pending study completion. This operational analysis was reviewed jointly by the Human Research Protection Program and Quality, Safety & Value service line at the VA Puget Sound Health Care System and determined to not constitute human subjects research"

Clinical • Immunomodulating • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Venous Thromboembolism

Patient perspectives on the clinical management of pregnancy-related hypertension: A qualitative data analysis. (PubMed, Womens Health (Lond)) - "Patient experiences emphasize the need for healthcare providers to adopt more intentional, personalized approaches to care. It is crucial to acknowledge existing power dynamics and take deliberate steps to ensure that care remains patient centered. An intentional approach enhances patient confidence in the care team, promotes greater patient activation, and supports uptake of preventive measures such as low-dose aspirin."

Journal • Cardiovascular • Hypertension

Anti-β2GPI/HLA-DR Antibody, Chronic Endometritis, and Uterine Endometrial Microbiome in Women with Recurrent Pregnancy Loss: A Prospective Cohort Study. (PubMed, Microorganisms) - "Women with anti-β2GPI/HLA-DR antibody, CE, and endometrial dysbiosis received low-dose aspirin and heparin, antibiotics, and probiotics, respectively...All 9 pregnancies with anti-β2GPI/HLA-DR antibody, 13 (92.9%) of 14 pregnancies with CE, and 24 (92.3%) of 26 pregnancies with NLDM-2 resulted in live birth. Assessment of these new tests may be clinically useful for reducing the proportion of unexplained RPL, and for providing high live birth rates if women receive relevant treatments."

Journal • Endometriosis • SDC1

Acanthamoeba castellanii: Non-Steroidal Anti-Inflammatory Drugs Affect Adhesion, Motility, and Encystment, Suggesting a Link with a gp63-like Protein Candidate. (PubMed, Pathogens) - "This exploratory study evaluated whether three non-steroidal anti-inflammatory drugs (NSAIDs)-acetylsalicylic acid, ibuprofen, and diclofenac (100 µM)-modulate pathogenicity-related processes in A. castellanii and explored the involvement of a gp63-like protein during encystment and adhesion. Colocalization analysis showed increased spatial overlap between gp63-like protein and F-actin in cysts (~40%) and migrating trophozoites (~20%) compared with non-stimulated forms (~3.8%). Collectively, these findings suggest that NSAID-sensitive pathways influence host interaction, migration, and encystment in A. castellanii and allow for the proposal of gp63-like protein as a putative molecular component of the NSAIDs sensitive pathways."

Journal • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology

Does Administration of Low-Dose Aspirin Enhance the Efficacy of Psychotropic Drugs in Patients with Bipolar Disorder, Schizophrenia, and Schizoaffective Disorder? (PubMed, Pharmaceuticals (Basel)) - " Overall, LDA co-treatment was associated with better clinical outcomes among patients with BD, schizophrenia, and SAD. Follow-up large-scale epidemiological studies and prospective randomized clinical trials are needed to examine the therapeutic potential of add-on LDA to psychotropic medications."

Clinical • Journal • Bipolar Disorder • CNS Disorders • Inflammation • Mental Retardation • Mood Disorders • Psychiatry • Schizophrenia

Evaluation of safety and affection of variable duration of dual antiplatelet therapy using aspirin plus ticagrelor after successful percutaneous coronary intervention for diabetic patients with acute coronary syndrome. (PubMed, BMC Cardiovasc Disord) - No abstract available

Journal • Acute Coronary Syndrome • Cardiovascular • Diabetes • Metabolic Disorders

Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies. (PubMed, J Clin Med) - "Contemporary European and North American guidelines endorse an increasingly individualized approach, moving away from rigid "one-size-fits-all" dual antiplatelet therapy (DAPT) duration and intensity and incorporating dual pathway inhibition with low-dose rivaroxaban plus aspirin in selected high-risk CCS and PAD patients. Evidence gaps remain substantial, particularly in patients with overlapping vascular territories, AF plus atherosclerotic disease, and after ischemic stroke of complex or mixed mechanisms. This narrative review summarizes current evidence and guideline-based strategies in major atherosclerotic settings, proposes a unifying conceptual framework, and highlights key uncertainties and research directions for truly personalized antithrombotic care."

Journal • Review • Acute Coronary Syndrome • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Geriatric Disorders • Hematological Disorders • Ischemic stroke • Peripheral Arterial Disease • Thrombosis

Ciprofloxacin Exposure Impairs Neurogenesis and E/I balance in Human Cortical Organoids. (PubMed, Neuropharmacology) - "Importantly, aspirin significantly alleviated CPFX-induced mitochondrial dysfunction, restored ATP and ROS levels, and stabilized neuronal electrophysiological activity in primary neurons, underscoring its potential as a therapeutic intervention. Overall, CPFX can induce a broader neuropathological phenotype and impair both mitochondrial function and neurogenesis in hCOs, potentially through a mechanism mediated by FOXG1 disruption. These findings offer novel insights into CPFX-induced neurotoxicity and imply FOXG1 as a promising intervention target."

Journal • Developmental Disorders • Epilepsy • Metabolic Disorders • FOXG1

Antithrombotic Therapy in Percutaneous Atrial Structural Interventions. (PubMed, J Cardiovasc Dev Dis) - "Following PFO and ASD closure, antiplatelet-only regimens-typically brief dual antiplatelet therapy followed by aspirin-are widely used, with evidence suggesting that simplified or abbreviated strategies may be sufficient in selected patients. Despite extensive clinical experience, high-quality comparative trials are limited, and optimal therapy, duration, and surveillance remain debated. Standardized imaging definitions, randomized studies, and individualized risk-based frameworks are needed to optimize antithrombotic care after atrial structural interventions."

Journal • Review • Thrombosis

Kaposiform hemangioendothelioma associated with coagulopathy and treated with low-dose aspirin: a three-case series. (PubMed, An Bras Dermatol) - No abstract available

Journal • Hematological Disorders • Oncology

Endometrial Carcinomas Are Enriched for Acetylsalicylic Acid (ASA)-Associated PI3K Pathway Mutations (USCAP 2026) - "This study demonstrates a high prevalence of ASA-related PI3KPathMut in EC, similar to CRC. Prior studies of ASA's effect on EC outcomes have been largely retrospective, have not been biomarker-based (PI3KPathMut status unknown), and have had conflicting results. These results suggest that the efficacy of ASA in EC with known PI3K pathway mutations may be deserving of future prospective study."

Colorectal Cancer • Endometrial Cancer • Gynecologic Cancers • Oncology • Solid Tumor • PIK3CA • PIK3R1 • PTEN

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (clinicaltrials.gov) - P4 | N=60 | Completed | Sponsor: Vanderbilt University Medical Center | Active, not recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Jul 2025 | Trial primary completion date: Mar 2026 ➔ Jul 2025

Trial completion • Trial completion date • Trial primary completion date • Cardiovascular • Hematological Disorders • Peripheral Arterial Disease • Thrombosis • ICAM1

IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (clinicaltrials.gov) - P3 | N=137 | Completed | Sponsor: Royal College of Surgeons, Ireland | N=300 ➔ 137 | Unknown status ➔ Completed

Enrollment change • Trial completion • Diabetes • Gestational Diabetes • Metabolic Disorders

Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Tang-Du Hospital

New trial • Infertility • Sexual Disorders

Mitigating Placental Inflammation is Necessary for Improved Fetal Outcomes following Maternal H1N1 Infection (IMMUNOLOGY 2026) - "As H1N1 does not replicate outside the respiratory tract, identifying mechanisms for mitigating placental inflammation will be critical for improved outcomes. To distinguish the contributions of viral replication and maternal immune activation, infected pregnant CD1 dams were treated with oseltamivir and/or low-dose acetylsalicylic acid (LDA), beginning 2 days post-infection and continuing until euthanasia at 6 days post-infection. OST reduced lung viral burden and maternal morbidity but had limited impact on placental immune and endocrine dysregulation. Given that OST and LDA are approved for use during pregnancy, these findings highlight their combined therapeutic potential for treating influenza infection in pregnancy."

Late-breaking abstract • Infectious Disease • Inflammation • Influenza • Respiratory Diseases • CD8 • IFNG • IL17A

Early aspirin withdrawal versus dual antiplatelet therapy in high-risk patients after percutaneous coronary intervention: Meta-analysis of randomized trials. (PubMed, PLoS Med) - "Among high-risk post-PCI patients on ticagrelor/prasugrel, discontinuing aspirin within 3 months reduces bleeding without an ischemic trade-off versus DAPT. Immediate aspirin noninitiation or cessation should be avoided; timing should be individualized to bleeding and ischemic risk. PROSPERO: CRD420251167706."

Clinical • Journal • Retrospective data • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

One-Year Outcomes of Dual Versus Single Antithrombotic Therapy Following Iliac Vein Stenting for Acute Iliofemoral DVT. (PubMed, Angiology) - "This single-center retrospective study compared rivaroxaban monotherapy (n = 84) versus combined rivaroxaban and aspirin therapy (n = 84) in 168 patients undergoing iliac vein stenting for acute iliofemoral DVT. The reduction in thrombotic outcomes with dual therapy remained significant after propensity score matching adjusted for baseline characteristics. These results suggest that a strategy combining anticoagulant and antiplatelet therapy after iliac vein stenting may more effectively prevent thrombus recurrence and stent-related thrombosis without a significant increase in bleeding risk, offering a potential tailored approach for this patient population."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Timing matters: early antiplatelet therapy optimizes alteplase treatment in acute ischemic stroke. (PubMed, Ann Med) - "Subgroup analyses indicated that aspirin was the primary contributor to the observed benefits. Initiating APT within 24 h after alteplase improves neurological and functional recovery in AIS without increasing hemorrhagic risk. These findings suggest that earlier APT may be considered in post-thrombolysis management, potentially informing revisions to current guideline recommendations."

Journal • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Efficacy, Safety, and Net Clinical Benefit of Post-Atrial Fibrillation Ablation Anticoagulation. (PubMed, Pacing Clin Electrophysiol) - "This meta-analysis suggests that after successful AF ablation, continuing OAC does not significantly reduce stroke risk compared to cessation or switching to aspirin, but it may increase major bleeding. While NCB trends favor cessation, the low absolute event rates and the risk of silent AF recurrence necessitate caution."

Journal • Review • Atrial Fibrillation • Cardiovascular

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF CURCUMIN TO REDUCE MUCOSITIS IN AUTOLOGOUS TRANSPLANT SETTING (EBMT 2026) - P3 | "Those receiving anti-oxidants, NSAIDs, aspirin or systemic steroids for past 3 months with last dose taken within a week prior to enrolment were excluded. This double-blinded, placebo-controlled, phase III RCT failed to demonstrate benefit of curcumin in reducing incidence of grade III/IV mucositis associated with high-dose melphalan."

Clinical • P3 data • Bone Marrow Transplantation • Mucositis • Stomatitis • Transplantation

THE USE OF GCSF FOR STEM CELLS MOBILIZATION IN PATIENTS WITH SICKLE CELL DISEASE TREATED WITH GENE THERAPY (EBMT 2026) - " The objective is to assess the safety, feasibility, and effectiveness of combining GCSF with plerixafor in stem cell mobilization for Exa-cel gene therapy in SCD patients.Retrospective analysis of 13 SCD patients undergoing autologous CD34⁺ cell collection...Hydroxyurea held for 8 weeks; exchange transfusions targeting HbS <30% (Group A/B) or <20% (Group C). Inpatient management included hydration and aspirin prophylaxis... The combination of G-CSF with plerixafor resulted in improved collection of the target cell dose for gene therapy compared to plerixafor alone. No safety concerns were observed with G-CSF use in SCD patients managed under a specific protocol. Further evaluation in a larger cohort, including detailed analysis of the cellular characteristics of collected cells, is planned."

Clinical • Gene therapy • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • CD34

STEM CELL MOBILISATION FOR GENE THERAPY IN ADOLESCENT PATIENTS WITH SICKLE CELL DISEASE: EXPERIENCE FROM THE FIRST THREE PATIENTS IN THE UK (EBMT 2026) - " Three teenagers (ages 14, 15 and 16) with severe SCD were referred for exagamglogene autotemcel (Casgevy®)...Patient 1 and Patient 2 experienced circuit clotting during Cycle 1, and Patient 3 had two G-CSF doses omitted in Cycle 2 because of the mild pain, successfully managed with oral morphine.Peak WBC counts during Cycle 3 were 89.9 × 10⁹/L, 103.2 × 10⁹/L and 70.9 × 10⁹/L for Patients 1, 2 and 3 respectively... The combination of G-CSF and plerixafor with an elevated WBC threshold, preceded by RCE and supported by targeted thromboprophylaxis with LMWH and Aspirin, proved safe, well tolerated, and markedly more effective than plerixafor alone in adolescents undergoing mobilisation for SCD gene therapy. This modified protocol achieved consistently adequate CD34^+ yields after prior mobilisation failures.We propose this approach as a potential first-line mobilisation strategy for SCD patients preparing for autologous gene therapy, with the aim of..."

Clinical • Gene therapy • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • CD34 • SCD

ERYTHROCYTOSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE (EBMT 2026) - "Post-transplant erythrocytosis is an uncommon complication. In our single-centre cohort, predominantly affecting young male long-term survivors, it followed a generally benign clinical course and was not associated with clonal myeloproliferative disease, as evidenced by normal erythropoietin levels and the absence of JAK2 mutations among evaluable patients. Patients were successfully managed with low-dose aspirin, with or without therapeutic phlebotomy."

Clinical • Acute Myelogenous Leukemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Complement-mediated Rare Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Myelofibrosis • Myeloproliferative Neoplasm • Myocardial Infarction • Paroxysmal Nocturnal Hemoglobinuria • Polycythemia Vera • Rare Diseases • Transplantation • JAK2